Premium
Treatment of facial superficial basal cell carcinomas with imiquimod 5% cream
Author(s) -
Mirza B.,
De'Ambrosis B.
Publication year - 2003
Publication title -
clinical and experimental dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.587
H-Index - 78
eISSN - 1365-2230
pISSN - 0307-6938
DOI - 10.1046/j.1365-2230.28.s1.6.x
Subject(s) - imiquimod , dermatology , basal cell carcinoma , medicine , basal cell , skin cancer , pathology , cancer
Summary Basal cell carcinoma (BCC) is the most common form of skin cancer and occurs predominantly as two forms, nodular or superficial. We report cases of two females who presented with facial BCCs, one with a 2‐month history of superficial BCC with a dual growth pattern (superficial BCC overlying a deep micronodular pattern BCC), and the other with a 4‐year history of superficial BCC. Both patients had undergone previous unsuccessful treatments. Differing responses of facial superficial BCCs were observed following daily treatment with imiquimod 5% cream over 6 weeks. This included a treatment failure in the BCC with a dual growth pattern and complete clearance of the other superficial BCC.